相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cost-Effectiveness of Venous Thromboembolism Prophylaxis During Neoadjuvant Chemotherapy for ovarian Cancer
Emma S. Ryan et al.
JCO ONCOLOGY PRACTICE (2021)
Cost-Effectiveness Analysis of Direct Oral Anticoagulants Versus Vitamin K Antagonists for Venous Thromboembolism in China
Ke-Xin Sun et al.
FRONTIERS IN PHARMACOLOGY (2021)
Antithrombotic Therapy for VTE Disease Second Update of the CHEST Guideline and Expert Panel Report
Scott M. Stevens et al.
CHEST (2021)
2019 ESC Guidelines for the dignosis and management of acute pulmonary embolism development Toed in colaboration with the European Respiratory Society (ERS)
Stavros Konstantinides et al.
EUROPEAN HEART JOURNAL (2020)
Autopsy Findings and Venous Thromboembolism in Patients With COVID-19
Dominic Wichmann et al.
ANNALS OF INTERNAL MEDICINE (2020)
Total costs of treating venous thromboembolism: implication of different cost perspectives in a Danish setting
Agnete Nielsen et al.
JOURNAL OF MEDICAL ECONOMICS (2019)
Rivaroxaban versus warfarin treatment among morbidly obese patients with venous thromboembolism: Comparative effectiveness, safety, and costs
Alex C. Spyropoulos et al.
THROMBOSIS RESEARCH (2019)
Causes of Sudden Unexpected Death in Schizophrenia Patients A Forensic Autopsy Population Study
Daming Sun et al.
AMERICAN JOURNAL OF FORENSIC MEDICINE AND PATHOLOGY (2019)
Rivaroxaban for non-valvular atrial fibrillation and venous thromboembolism in the Netherlands: a real-world data based cost-effectiveness analysis
Lisa Aniek de Jong et al.
JOURNAL OF MEDICAL ECONOMICS (2019)
Cost-effectiveness Evaluations Among the Direct Oral Anticoagulants for the Prevention and Treatment of Venous Thromboembolism: Systematic Review
Mohammad Al Mukdad et al.
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS (2019)
Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis
Jonathan AC Sterne et al.
HEALTH TECHNOLOGY ASSESSMENT (2017)
Rivaroxaban versus standard anticoagulation for symptomatic venous thromboembolism (REMOTEV observational study): Analysis of 6-month outcomes
Sebastien Gaertner et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2017)
Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences
Tereza Lanitis et al.
BMC HEALTH SERVICES RESEARCH (2017)
Non-vitamin K Oral Anticoagulants Versus Warfarin for Patients with Atrial Fibrillation: Absolute Benefit and Harm Assessments Yield Novel Insights
Cyrus R. Kumana et al.
CARDIOVASCULAR THERAPEUTICS (2016)
Global Burden of Thrombosis Epidemiologic Aspects
Aaron M. Wendelboe et al.
CIRCULATION RESEARCH (2016)
Vitamin K antagonist use: evidence of the difficulty of achieving and maintaining target INR range and subsequent consequences
Jeff R. Schein et al.
THROMBOSIS JOURNAL (2016)
Epidemiology of venous thromboembolism
John A. Heit
NATURE REVIEWS CARDIOLOGY (2015)
Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US
Alpesh Amin et al.
JOURNAL OF MEDICAL ECONOMICS (2015)
Cost-effectiveness analysis of treatment of venous thromboembolism with rivaroxaban compared with combined low molecular weight heparin/vitamin K antagonist
Luke Bamber et al.
THROMBOSIS JOURNAL (2015)
Thrombosis A Major Contributor to Global Disease Burden
G. E. Raskob et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2014)
Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials
N. van Es et al.
BLOOD (2014)
Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis
Sam Schulman et al.
CIRCULATION (2014)
Editor's Choice - Efficacy and Safety of the New Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Edoxaban in the Treatment and Secondary Prevention of Venous Thromboembolism: A Systematic Review and Meta-analysis of Phase III Trials
S. K. Kakkos et al.
EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY (2014)
Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta- analysis
T. van der Hulle et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2014)
Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
Harry R. Bueller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Giancarlo Agnelli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation
Anuraag R. Kansal et al.
HEART (2012)
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
Harry R. Buller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Oral Rivaroxaban for Symptomatic Venous Thromboembolism.
Rupert Bauersachs et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism.
Sam Schulman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients
S Schulman et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2005)
Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism - A meta-analysis
LA Linkins et al.
ANNALS OF INTERNAL MEDICINE (2003)
分享论文
